围术期GLP-1受体激动剂使用与结局:全国前瞻性多中心队列研究
英国119家中心前瞻性纳入47039例麻醉下手术成人,1348例(2.9%)术前3个月内使用GLP-1受体激动剂。GLP-1 RA组肺误吸和/或反流发生率为1.41%(95%CI 0.85-2.19%),非GLP-1 RA组为0.12%(95%CI 0.09-0.16%),OR 11.39(95%CI 6.47-20.05),P<0.001;围术期管理策略差异大,事件多发生于麻醉苏醒期。
要点
- 约1/36麻醉患者围术期使用GLP-1 RA,管理策略差异大。
- GLP-1 RA组肺误吸和/或反流发生率1.41%,显著高于非使用组的0.12%。
- 使用GLP-1 RA者肺误吸和/或反流最常发生于麻醉苏醒期。
核心结论
- 麻醉患者中约1/36使用GLP-1 RA,围术期管理策略差异大。
- GLP-1 RA组肺误吸和/或反流发生率显著高于非GLP-1 RA组,OR 11.39(95%CI 6.47-20.05),P<0.001。
研究设计与样本
- 英国119家中心全国前瞻性多中心队列研究,纳入47039例在麻醉医生照护下接受择期或急诊手术的成人。
- 筛查指标手术前3个月内GLP-1 RA使用情况,收集患者、手术、麻醉及结局数据。
- 主要结局为接受GLP-1 RA的患者比例,次要结局包括围术期管理、麻醉与气道管理及肺误吸和/或反流发生率。
主要发现
- 47039例中1348例(2.9%)报告使用GLP-1 RA。
- 非GLP-1 RA组肺误吸和/或反流发生率为57/45691(0.12%,95%CI 0.09-0.16%)。
- GLP-1 RA组肺误吸和/或反流发生率为19/1348(1.41%,95%CI 0.85-2.19%),OR 11.39(95%CI 6.47-20.05),P<0.001。
- 使用GLP-1 RA的患者中,肺误吸和/或反流最常发生于麻醉苏醒期。
- 围术期停药、麻醉及气道管理策略存在差异。
临床怎么用
- 麻醉科医生应在本前识别GLP-1 RA使用患者,并关注其肺误吸和/或反流风险。
- 对使用GLP-1 RA的患者,尤其需关注麻醉苏醒期的肺误吸和/或反流风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Peri-operative glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with delayed gastric emptying. It is unclear what proportion of patients having anaesthetic care are receiving GLP-1 RAs; what strategies are used in their peri-operative management; and whether the incidence of pulmonary aspiration and/or regurgitation is greater in this population. METHODS: We performed a national prospective multicentre cohort study of adults undergoing elective or emergency procedures under the care of an anaesthetist. Patients were screened for GLP-1 RA use in the 3 months before the index procedure. Data were collected on patient, procedure, anaesthesia and outcomes, including pulmonary aspiration and regurgitation. The primary outcome was the proportion of patients receiving GLP-1 RAs. Secondary outcomes described the pre-operative management of GLP-1 RAs; anaesthesia and airway management in patients receiving GLP-1 RAs; and the incidence of pulmonary aspiration and/or regurgitation. RESULTS: Of 47,039 patients from 119 sites across the UK, 1348 (2.9%) reported receiving GLP-1 RAs. Peri-operative management was variable regarding drug cessation, anaesthesia and airway management. The incidence (95%CI) of pulmonary aspiration and/or regurgitation in the non-GLP-1 RA cohort was 57/45,691 (0.12% (0.09-0.16%)) and in the GLP-1 RA cohort was 19/1348 (1.41% (0.85-2.19%)); odds ratio (95%CI) 11.39 (6.47-20.05), p < 0.001. In patients receiving GLP-1 RAs, pulmonary aspiration and/or regurgitation occurred most frequently during emergence from anaesthesia. DISCUSSION: In this national study, 1 in 36 patients undergoing anaesthesia care received GLP-1 RAs, and their peri-operative management was variable. A range of airway management techniques aiming to reduce pulmonary aspiration risk were observed but, despite this, the incidence of pulmonary aspiration and/or regurgitation was 1 in 71 in people receiving GLP-1 RAs. WHAT WE DID: We studied adults having surgery or other procedures with an anaesthetist at 119 hospitals across the UK. We looked at how many patients were taking GLP‐1 medicines, such as those used to treat diabetes or help with weight loss (for example, Mounjaro or Wegovy). We also looked at how these medicines were managed around the time of anaesthesia and how often patients had stomach contents come back up into the mouth (regurgitation) or enter their lungs. WHY WE DID IT: GLP‐1 medicines can slow down how quickly the stomach empties. This could mean that food or liquid is still in the stomach during anaesthesia, which may increase the risk of it entering the lungs if the patient regurgitates. We wanted to find out how common GLP‐1 medicine use was in patients having anaesthesia and whether these patients had a higher risk of regurgitation or stomach contents entering their lungs. WHAT WE FOUND: Out of 47,039 patients, 1348 (about 1 in 36) were taking GLP‐1 medicines. There were big differences in how these medicines were managed before surgery and in how anaesthesia and airway care were provided. Regurgitation or stomach contents entering the lungs happened in about 1 in 71 patients taking GLP‐1 medicines, compared with about 1 in 802 patients who were not taking them. This means the risk may be higher in people taking GLP‐1 medicines. These events most often happened as patients were waking up from anaesthesia.
引用
- Potter TE, Cronin JN, Kua J, et al. Peri-operative glucagon-like peptide-1 receptor agonist use and outcomes: a national prospective multicentre cohort study. Anaesthesia. 2026. PMID: 42748560. doi:10.1111/anae.70380
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。